RxDoctor Payments Data

Robert Cho, MD

Hospitalist · Irvine, CANPI 1760578512

Payments from drug & device makers

$2,852in general payments, 2019–2025

Across 40 payments — averaging $71.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$1K
  • Johnson & Johnson$516
  • Inari Medical, Inc.$375
  • AbbVie$231
  • Globus Medical$175
  • Medtronic$110
  • plus $312 from 7 others

What the payments were for

  • Travel & lodging$1,02836%
  • Food & beverage$1,82464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,852 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$169,872
Medicare patients
404
Services billed
1,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$21,116
XareltoRivaroxaban20$8,083
Amiodarone Hcl19$2,097
Memantine Hcl23$1,422
Pantoprazole Sodium42$597
Olmesartan Medoxomil11$534
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav52$443
Lamotrigine13$322
Latanoprost17$311
Hydralazine Hcl13$304
Gabapentin23$240
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$237
Metoprolol Succinate28$204
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$165
Cefdinir17$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$516$8,08320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →